MedPath

Famotidine

Generic Name
Famotidine
Brand Names
Duexis, Duo Fusion, Fluxid, Good Sense Acid Reducer, Pepcid, Pepcid Complete, Zantac Reformulated Aug 2022
Drug Type
Small Molecule
Chemical Formula
C8H15N7O2S3
CAS Number
76824-35-6
Unique Ingredient Identifier
5QZO15J2Z8
Background

Famotidine is a competitive histamine-2 (H) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children. Compared to other H receptor antagonists, famotidine displays high selectivity towards this receptor; in a study consisting of healthy volunteers and patients with acid hypersecretory disease, famotidine was about 20 to 50 times more potent at inhibiting gastric acid secretion than cimetidine and eight times more potent than ranitidine on a weight basis. Famotidine is used in various over-the-counter and off-label uses. While oral formulations of famotidine are more commonly used, the intravenous solution of the drug is available for use in hospital settings.

Indication

Famotidine is indicated in pediatric and adult patients (with the bodyweight of 40 kg and above) for the management of active duodenal ulcer (DU), active gastric ulcer, symptomatic non-erosive gastroesophageal reflux disease (GERD), and erosive esophagitis due to GERD, diagnosed by biopsy.

It is also indicated in adult patients for the treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison Syndrome, multiple endocrine neoplasias) and reduction of the risk of DU recurrence.

The intravenous formulation of famotidine is available for some hospitalized patients with pathological hypersecretory conditions or intractable ulcers or as an alternative to the oral dosage form for short-term use in patients who are unable to take oral medication.

Over-the-counter famotidine is used for the management and prevention of heartburn caused by gastroesophageal reflux in children and adults. Off-label uses of famotidine include the reduction of NSAIDs-associated gastrointestinal effects, treatment of refractory urticarial, prevention of stress ulcer in critically-ill patients, and symptomatic relief of gastritis.

Associated Conditions
Chronic Back Pain, Duodenal Ulcer, Erosive Esophagitis, Extra-Articular Rheumatism, Gastritis, Heartburn, Helicobacter Pylori Infection, Multiple Endocrine Neoplasia, Muscle Spasms, Nonspecific Pain Post Traumatic Injury, Osteoarthritis (OA), Postoperative pain, Stress Ulcers, Symptomatic Non-erosive Gastroesophageal Reflux Disease, Zollinger-Ellison Syndrome, Active Gastric ulcer, Acute Duodenal Ulcers, Gastrointestinal ulceration, Pathological hypersecretory conditions

Role of Famotidine in the Clinical Improvement of COVID-19 Patients.

Phase 3
Completed
Conditions
Covid19
Interventions
First Posted Date
2020-08-07
Last Posted Date
2021-10-26
Lead Sponsor
Chattogram General Hospital
Target Recruit Count
208
Registration Number
NCT04504240
Locations
🇧🇩

M. Abdur Rahim Medical College Hospital, Dinājpur, Bangladesh

🇧🇩

Chattogram General Hospital, Chittagong, Bangladesh

I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients

First Posted Date
2020-07-27
Last Posted Date
2024-03-19
Lead Sponsor
QuantumLeap Healthcare Collaborative
Target Recruit Count
1500
Registration Number
NCT04488081
Locations
🇺🇸

Columbia University Medical Center, New York, New York, United States

🇺🇸

Sanford Health, Sioux Falls, South Dakota, United States

🇺🇸

University of Rochester Medical Center, Rochester, New York, United States

and more 33 locations

Study to Assess the Effect of Acid-reducing Agent Famotidine on the Drug Levels of BMS-986256 in Healthy Participants

Phase 1
Completed
Conditions
Healthy Participants
Interventions
First Posted Date
2020-07-14
Last Posted Date
2025-02-06
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
35
Registration Number
NCT04470778
Locations
🇺🇸

ICON (LPRA) - Salt Lake, Salt Lake City, Utah, United States

A Study to Assess the Effects of Acid-Reducing Agent(s) on JNJ-64417184 in Healthy Participants

Phase 1
Completed
Conditions
Healthy Participants
Interventions
First Posted Date
2020-07-01
Last Posted Date
2025-02-03
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
14
Registration Number
NCT04453189
Locations
🇳🇱

PRA Health Sciences Onderzoekscentrum Groningen, locatie Martini, Groningen, Netherlands

Histamine H1/H2 Receptors and Training Adaptations

Not Applicable
Completed
Conditions
Exercise Training
Physical Activity
Interventions
Other: Lactose
Other: High-intensity interval training (HIIT)
First Posted Date
2020-06-29
Last Posted Date
2024-06-07
Lead Sponsor
University Ghent
Target Recruit Count
19
Registration Number
NCT04450134
Locations
🇧🇪

Department of Movement and Sports Sciences, Ghent University, Gent, Oost-Vlaanderen, Belgium

Famotidine Outpatient COVID-19 Treatment Study

Completed
Conditions
COVID-19
Interventions
First Posted Date
2020-05-15
Last Posted Date
2023-05-06
Lead Sponsor
Northwell Health
Target Recruit Count
10
Registration Number
NCT04389567
Locations
🇺🇸

Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, United States

A Study in Healthy Male Subjects to Investigate the Effect of Famotidine and Efavirenz on the Way the Body Takes up, Distributes, and Gets Rid of Daridorexant.

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2020-05-15
Last Posted Date
2020-09-16
Lead Sponsor
Idorsia Pharmaceuticals Ltd.
Target Recruit Count
24
Registration Number
NCT04390334
Locations
🇩🇪

CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany

A Phase II Trial of Neoadjuvant Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With Chemoradiation

Phase 2
Recruiting
Conditions
Gastric Cancer
Stomach Cancer
Interventions
Radiation: 3D conformal or intensity modulated radiotherapy
Procedure: Surgical resection
Radiation: Adjuvant Chemotherapy
First Posted Date
2020-03-16
Last Posted Date
2023-11-14
Lead Sponsor
Icahn School of Medicine at Mount Sinai
Target Recruit Count
29
Registration Number
NCT04308837
Locations
🇺🇸

Icahn School of Medicine at Mount Sinai, New York, New York, United States

🇺🇸

Mount Sinai St. Luke's, New York, New York, United States

🇺🇸

Mount Sinai West, New York, New York, United States

Antihistamines in Eosinophilic Esophagitis

Phase 2
Terminated
Conditions
Eosinophilic Esophagitis
Interventions
First Posted Date
2020-01-30
Last Posted Date
2022-12-20
Lead Sponsor
Mayo Clinic
Target Recruit Count
1
Registration Number
NCT04248712
Locations
🇺🇸

Mayo Clinic, Jacksonville, Florida, United States

A Study Comparing the Effects of Famotidine Pretreatment and of Food on the Relative Bioavailability of BMS-986165 in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy Participants
Interventions
First Posted Date
2019-12-24
Last Posted Date
2020-04-21
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
18
Registration Number
NCT04209699
Locations
🇺🇸

PRA Health Sciences - Salt Lake, Salt Lake City, Utah, United States

© Copyright 2025. All Rights Reserved by MedPath